EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The evaluation, management, and future of indolent systemic mastocytosis

Arjun Syal, Jennifer Toh, Alissa McInerney, Douglas Tremblay

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06475-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Hematology, 2025. Verfasst von Arjun Syal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave, New York, NY, 10019, USA. Hauptthemen laut MEDLINE: Mastocytosis, Systemic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Indolent systemic mastocytosis (ISM) is a chronic hematologic malignancy that has traditionally been managed primarily by allergists. However, with improved molecular diagnostics such as droplet digital PCR (ddPCR) for KIT D816V on bone marrow aspirate specimens and the availability of targeted therapies against KIT, hematologists are increasingly involved in the care of these patients. This review summarizes current understanding of the evaluation, diagnosis, treatment, and future therapeutic strategies in ISM, with a focus on clinically relevant insights for hematologists. We begin by emphasizing the broad and often debilitating range of ISM symptoms, which frequently include cutaneous, gastrointestinal, and mediator symptoms. The diagnostic workup underscores the importance of molecular testing for KIT mutations and bone marrow evaluation, clarifying the clinical scenarios in which each test should be utilized. Furthermore, management strategies start with symptomatic support and can include targeted KIT inhibition, such as avapritinib, for patients with refractory disease. ISM is a non-advanced subtype of systemic mastocytosis characterized by a wide spectrum of symptoms without evidence of organ damage. While many patients have stable disease, a subset may experience persistent morbidity or disease progression. Future directions include improving early recognition, validating biomarkers for monitoring and therapeutic response, and evaluating investigational therapies aimed at modifying disease course.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mastocytosis, SystemicHumansProto-Oncogene Proteins c-kitDisease ManagementMutationPyrazolesPyrrolesTriazinesAvapritinib

Stichwörter der Autor:innen

AvapritinibDdPCRIndolent systemic mastocytosisKITSystemic mastocytosis

Substanzen

Proto-Oncogene Proteins c-kitPyrazolesPyrrolesTriazinesAvapritinibKIT protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave, New York, NY, 10019, USA.
  • Weill Cornell Medical College, 525 East 68th Street, New York, NY, 10065, USA.
  • ENT and Allergy Associates- West Side, 620 Columbus Avenue, 2nd Floor, New York, NY, 10024, USA.
  • Equity Medical, LLC, 200 Amsterdam Ave, New York, NY, 10023, USA.
  • Department of Pediatrics and Medicine, Northwell Health Division of Allergy Immunology, 300 Community Dr, Manhasset, NY, 11030, USA.
  • Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY, 10029, USA. douglas.tremblay@mssm.edu.

Zitieren

APA

Syal, A., Toh, J., McInerney, A., & Tremblay, D. (2025). The evaluation, management, and future of indolent systemic mastocytosis. Annals of Hematology. https://doi.org/10.1007/s00277-025-06475-y

Vancouver

Syal A, Toh J, McInerney A, Tremblay D. The evaluation, management, and future of indolent systemic mastocytosis. Annals of Hematology. 2025. doi:10.1007/s00277-025-06475-y

BibTeX
@article{Syal2025,
  author = {Syal, Arjun and Toh, Jennifer and McInerney, Alissa and Tremblay, Douglas},
  title = {The evaluation, management, and future of indolent systemic mastocytosis},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06475-y}
}
Kostenlos starten →